EGFR and metastatic colorectal cancer: The survival of metastatic colorectal cancer (mCRC) patients significantly improved in the last 20 years with the introduction of target-oriented drugs [anti-EGFR (Epidermal Growth Factor Receptor) and anti-angiogenic agents] associated with chemotherapy (fluoropirimidines, oxaliplatin and irinotecan); however, it still very rarely encompasses 30 months (3).